HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System

Author(s): Sylvia Fitting, Rosemarie M. Booze, Charles F. Mactutus

Journal Name: Current HIV Research
HIV and Viral Immune Diseases

Volume 13 , Issue 1 , 2015

Become EABM
Become Reviewer
Call for Editor


In 2014, 3.2 million children (< 15 years of age) were estimated to be living with HIV and AIDS worldwide, with the 240,000 newly infected children in the past year, i.e., another child infected approximately every two minutes [1]. The primary mode of HIV infection is through mother-to-child transmission (MTCT), occurring either in utero, intrapartum, or during breastfeeding. The effects of HIV-1 on the central nervous system (CNS) are putatively accepted to be mediated, in part, via viral proteins, such as Tat and gp120. The current review focuses on the targets of HIV-1 proteins during the development of the dopamine (DA) system, which appears to be specifically susceptible in HIV-1-infected children. Collectively, the data suggest that the DA system is a clinically relevant target in chronic HIV-1 infection, is one of the major targets in pediatric HIV-1 CNS infection, and may be specifically susceptible during development. The present review discusses the development of the DA system, follows the possible targets of the HIV-1 proteins during the development of the DA system, and suggests potential therapeutic approaches. By coupling our growing understanding of the development of the CNS with the pronounced age-related differences in disease progression, new light may be shed on the neurological and neurocognitive deficits that follow HIV-1 infection.

Keywords: Pediatric HIV/AIDS, development, Tat, gp120, dopamine, neurocognitive impairment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 20 January, 2015
Page: [21 - 42]
Pages: 22
DOI: 10.2174/1570162X13666150121110731

Article Metrics

PDF: 81